Xenetic Biosciences
XBIO | NASDAQ
$1.49
-$0.17 (-10.24%)
At close: Nov 16, 2026, 4:00 PM ET
$1.60
+$0.11 (+7.72%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-10.24%
(1D)No price chart data available for 1D timeframe.
Rating
23.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #961/1021 (Top 94%)
Key Statistics
Market Data
Market Cap $3.49M
1D Range
1.43 1.75
52W Range
1.43 4.67
Valuation (TTM)
PE -0.94
PB 0.79
EV/EBITDA 0.63
Valuation (NTM)
Forward PE N/A
Forward PEG -0.02
Price Target $0.00
Cash Flow
FCF Yield -66.4%
SBC Adj. FCF Yield -69.3%
SBC Impact -4.4%
Margins
Gross Margin 16.7%
Operating Margin -129.6%
FCF Margin -78.3%
Growth (CAGR)
Revenue 3Y | 5Y 7.9% |
24.8%
Dil EPS 3Y | 5Y 25.6% |
30.4%
FCF 3Y | 5Y 11.7% |
21.4%
Returns
ROA -57.9%
ROE -59.0%
ROIC -86.9%
Financial Health
Net Cash
$5.81M
Current Ratio 3.15
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is...
Sector Healthcare
Industry Biotechnology
Employees 2
IPO Date Jun 30, 2016
Website www.xeneticbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove XBIO